Modulators of the urokinase-type plasminogen activation system for cancer

Bibliography

• REUNING U, MAGDOLEN V, WILHELM O et al.: Multifunc-tional potential of the plasminogen activation system in tumor invasion and metastasis. Int. j Onc. (1998) 13:893–906.
   PubMed Web of Science ®Google Scholar
• RABBANI SA: Metalloproteases and urokinase inangiogenesis and tumor progression. In vivo (1998) 12:135–142.
   PubMed Web of Science ®Google Scholar
• CARMELIET P, MOONS L, LUNEN R et al: Urokinase-generated plasmin activates matrix metalloprote-inases during aneurysm formation. Nature Genet. (1997) 17:439–444.
   PubMed Web of Science ®Google Scholar
• PLOW EG, HERREN T, REDLITZ A, MILES LA and HOOVER-PLOW, J: The cell biology of the plasminogen system. FASEB J. (1995) 9:939–945.
   PubMed Web of Science ®Google Scholar
• ELLIS V, BERHRENDT N, DANO, K: Plasminogen activa-tion by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. J. Biol. Chem. (1991) 266:12752–12758.
   Google Scholar
• HANSEN AP, PETROS AM, MEADOWS RP et al.: Solution structure of the amino-terminal fragment of urokinase-type plasminogen activator. Biochemistry (1994) 33:4847–4864.
   PubMed Web of Science ®Google Scholar
• SPRAGGON G, PHILLIPS C, NOVAK UK et al.: The crystal structure of the catalytic domain of human urokinase-type plasminogen activator. Structure (1995) 3:681–691.
   PubMed Web of Science ®Google Scholar
• •First determination of the 3-dimensional structure of the catalytic domain of uPA.
   Google Scholar
• ROLDAN AL, CUBELLIS MV, MASUCCI MT et al.: Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, p lasmin dependent proteolysis. EMBOJ (1990) 9:467–474.
   PubMed Web of Science ®Google Scholar
• •Initial cloning and identification of the urokinase receptor.
   Google Scholar
• ESTREICHER A, WOHLWEND A, BELIN D, SCHLEUNINGWD and VASSALLI, J: Characterization of the cellular binding site for the urokinase-type plasminogen activator. j Biol. Chem. (1989) 264:1180–1189.
   PubMed Web of Science ®Google Scholar
• PLOUG M, BEHRENDT N, LOBER D and DANO, K: Proteinstructure and membrane anchorage of the cellular receptor for urokinase-type plasminogen activator. Sem. Thromb. Hemostasis (1991) 17:183–193.
   PubMed Web of Science ®Google Scholar
• PLOUG M, KJALKE M, RONNE E et al.: localization of the disulfide bonds in the NI-12-terminal domain of the cellular receptor for human urokinase-type plasmi-nogen activator. A domain structure belonging to a novel superfamily of glycolipid-anchored membrane proteins. J. Biol. Chem. (1993) 268:17539–17546.
   Google Scholar
• NAR H, BAUER M, STASSEN JM et al: Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation. j Mol. Biol. (2000) 297:683–695.
   Google Scholar
• NYKJAER A, CONESE M, CHRISTENSEN El etal.: Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. EMBO J. (1997) 16:2610–2620.
   Google Scholar
• •An elegant study of the dynamics of clearance of the components of the uPA system.
   Google Scholar
• CHAPMAN HA: Plasminogen activators, integrins and the coordinated regulation of cell adhesion and migration. Curr. Opin. Cell. Biol. (1997) 9:714–724.
   PubMed Web of Science ®Google Scholar
• •An up-to-date review on the relationships between proteolysis, adhesion and migration with respect to the uPA system.
   Google Scholar
• DENG G, ROYLE G, WANG S, CRAIN K, LOSKUTOFF D: Structural and functional analysis of the plasminogen activator inhibitor-1 binding motif in the somato-medin B domain of vitronectin. j Biol. Chem. (1996) 271:12716–12723.
   PubMed Web of Science ®Google Scholar
• DENG G, CURRIDEN SA, WANG S, ROSENBERG S and LOSKUTOFF, D: Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J. Cell Biol. (1996) 134:1563–1571.
   PubMed Web of Science ®Google Scholar
• •Clear presentation of the hypothesis that PAI-1 can induce cell detachment and hence perhaps increase metastatic potential of tumour cells.
   Google Scholar
• WEI Y, LUKASHEV M, SIMON DI et al.: Regulation of integrin function by the urokinase receptor. Science (1996) 273:1551–1555.
   PubMed Web of Science ®Google Scholar
• ••Seminal paper on the interaction of the uPA system ingeneral and the urokinase receptor in particular with integrins.
   Google Scholar
• CHAPMAN HA, WEI Y, SIMON DI and WALTZ, D: Role of urokinase receptor and caveolin in regulation of integrin signaling. Thromb. Haemost. (1999) 82:291–297.
   PubMed Web of Science ®Google Scholar
• SIMON DI, WEI Y, ZHANG L et al.: Identification of a urokinase receptor-integrin interaction site. Promis-cuous regulator of integrin function. j Biol. Chem. (2000) 275:10228–10234.
   Google Scholar
• WALTZ DA, FUJITA RM, YANG X et al.: Nonproteolytic role for the urokinase receptor in cellular migration in vivo. Am. J. Resp. Cell. Mol. Biol. (2000) 22:316–322.
   PubMed Web of Science ®Google Scholar
• MAY AE, KANSE SM, LUND LR et al.: Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 integrins in vivo. J. Exp. Med. (1998) 188:1029–1037.
   PubMed Web of Science ®Google Scholar
• ••First demonstration of the in vivo relevance of uPAR:integrininteractions.
   Google Scholar
• CARMELIET P, COLLEN D: Development and disease in proteinase-deficient mice: role of the plasminogen, matrix metalloproteinase and coagulation system. Thromb. Res. (1998) 91 :255–285.
   PubMed Web of Science ®Google Scholar
• SHAPIRO RL, DUQUETTE JG, ROSES DF et al.: Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals. Cancer Res. (1996) 56:3597–3604.
   PubMed Web of Science ®Google Scholar
• BUGGE TH, KOMBRINCK KW, XIAO Q eta].: Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice. Blood (1997) 90:4522–4531.
   Google Scholar
• BUGGE TH, LUND LR, KOMBRINCK KK et al: Reducedmetastasis of polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice. Oncogene (1998) 16:3097–3104.
   PubMed Web of Science ®Google Scholar
• HEYMANS S, LUTTUN A, NUYENS D et al.: Inhibition ofplasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nature Med. (1999) 5:1135–1142.
   PubMed Web of Science ®Google Scholar
• LUND LR, ROMER J, BUGGE TH et al.: Functional overlapbetween two classes of matrix-degrading proteases in wound healing. EMBO J. (1999) 18:4645–4656.
   PubMedGoogle Scholar
• GYETKO MR, SUD S, KENDALL T et al: Urokinasereceptor-deficient mice have impaired neutrophil recruitment in response to pulmonary Pseudomonas aeroginosainfection. Immunol (2000) 165:1513–1519.
   Google Scholar
• ANDREASEN PA, KJOLLER L, CHRISTENSEN L, DUFFY MJ: The urokinase-type plasminogen activator system in cancer metastasis: a review. Intl Cancer (1997) 72:1–22.
   PubMed Web of Science ®Google Scholar
• ••An excellent review on the role of the uPA system in tumourprogression.
   Google Scholar
• FOEKENS JA, PETERS HA, LOOK MP et al.: The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res. (2000) 60:636–643.
   PubMed Web of Science ®Google Scholar
• •Extensive study of the relationship between expression of uPA system proteins and prognosis in breast cancer.
   Google Scholar
• MIN HY, DOYLE, L, VITT CR et al.: Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res. (1996) 56:2428–2433.
   PubMedGoogle Scholar
• •Direct demonstration of the in vivo role of the uPA system in angiogenesis.
   Google Scholar
• LI H, LU H, GRISCELLI F et al: Adenovirus-mediateddelivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemi-nation in mice. Gene Ther. (1998) 5:1105–1113.
   PubMed Web of Science ®Google Scholar
• GOODSON RJ, DOYLE MV, KAUFMAN SE, ROSENBERG S: High-affinity urokinase receptor antagonists identi-fied with bacteriophage peptide display. Proc. Natl. Acad. Sci USA (1994) 91:7129–7133.
   PubMed Web of Science ®Google Scholar
• ••First identification of antagonists of the uPA:uPAR interac-tion not derived from the uPA sequence.
   Google Scholar
• STRATTON-THOMAS JR, MIN HY, KAUFMAN SE et al.:Yeast expression and phagemid display of the human urokinase plasminogen activator epidermal growth factor-like domain. Prot. Engin. (1995) 8:463–470.
   PubMedGoogle Scholar
• AGUIRRE-GHISO JA, KOVALSKI K, OSSOWSKI L: Tumordormancy induced by downreg-ulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J. Cell. Biol. (1999) 147:89–104.
   PubMed Web of Science ®Google Scholar
• •One of the more recent and compelling papers on urokinase receptor mediated signal transduction.
   Google Scholar
• PEDERSEN AN, BRUNNER N, HOYER-HANSEN G et al.:Determination of the complex between urokinase and its type-1 inhibitor in plasma from healthy donors and breast cancer patients. an. Chem. (1999) 45:1206–1213.
   Google Scholar
• TRESSLER RJ, PITOT PA, STRATTON JR et al.: Urokinasereceptor antagonists: discovery and application to in vivo models of tumor growth. APMIS (1999) 107:168–173.
   PubMed Web of Science ®Google Scholar
• NELSON AR, FINGLETON B, ROTHENBERG ML, MATRISIAN L: Matrix metalloproteinases: biologic activity and clinical implications. J. Clin. Oncol. (2000) 18:1135–1149.
   PubMed Web of Science ®Google Scholar
• •Up-to-date review on the latest clinical developments in the MMPI field.
   Google Scholar